SAB Biotherapeutics Inc (SABS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $266.66M
Last updated: Nov 17, 2026 at 4:10 PM ET
SAB Biotherapeutics Inc (SABS) Statistics
SAB Biotherapeutics (SABS) has a market cap of $266.66M and an enterprise value of $252.22M. Its share count is up 774.61% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 5.41% below the market cap, as cash exceeds debt.
| Market Cap | $266.66M |
|---|---|
| Enterprise Value | $252.22M |
| Latest price (Nov 17, 2026) | $2.95 |
Key Dates
The next earnings report is expected on Mar 8, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 8, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is down 8.95% over 52 weeks and trades 4.53% below its 50-day average.
| Beta (1Y) | 1.07 |
|---|---|
| 52-Week Change | -8.95% |
| 1-Month Change | +13.46% |
| 3-Month Change | -21.96% |
| 6-Month Change | -16.90% |
| 5-Year Change | -95.76% |
| Total Return (1Y) | -8.95% |
| Total Return (3Y CAGR) | -29.69% |
| Total Return (5Y CAGR) | -51.57% |
| Return vs SPY (1Y) | -36.11% |
| Max Drawdown (1Y) | -45.75% |
| Max Drawdown (3Y) | -88.58% |
| Sharpe Ratio (1Y) | -0.48 |
| Correlation with SPY (1Y) | 0.25 |
| 50-Day Average | $3.09 |
| 200-Day Average | $3.61 |
| 52-Week Range | $2.44 to $5.15 |
| RSI (14 Days) | 45.9 |
| Average Volume (20 Days) | 646.54K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 7.28x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 7.28x |
|---|---|
| Quick Ratio | 7.28x |
| Debt / Equity | 0.00x |
| Interest Coverage | 50.20x |
Returns and Efficiency
Return on equity is -38.18% over the last 12 months, against a 5-year average of -60.20%.
| Return on Equity (ROE) | -38.18% |
|---|---|
| Return on Assets (ROA) | -34.17% |
| ROE (5Y Average) | -60.20% |
| ROA (5Y Average) | -35.54% |
| ROIC (5Y Average) | -28.38% |
Scores
SABS has a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 3 of 9 |
|---|---|
| Piotroski Strength | Average |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Gross Profit | -$763.30K |
| Operating Income | -$85.04M |
| Pretax Income | -$80.52M |
| Net Income | -$80.52M |
| Reported EPS (TTM) | -$1.28 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 89.51% of the $235.64M in total assets.
| Cash and Equivalents | $14.44M |
|---|---|
| Total Debt | $0 |
| Net Cash | $14.44M |
| Net Cash Per Share | $0.15 |
| Working Capital | $92.94M |
| Shareholder Equity | $210.92M |
| Book Value Per Share | $2.26 |
| Total Assets | $235.64M |
| Total Liabilities | $24.72M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $4.85M of capital spending, operating cash flow left -$58.76M of free cash flow.
| Operating Cash Flow | -$53.91M |
|---|---|
| Capital Expenditures | $4.85M |
| Free Cash Flow | -$58.76M |
| FCF Per Share | -$0.65 |
| Depreciation and Amortization | $3.17M |
Trailing 12 months through Sep 30, 2026.
Dividends and Yields
SABS does not pay a dividend. Its free cash flow yield is -21.36%.
| FCF Yield | -21.36% |
|---|---|
| Buyback Yield | 0.00% |
| Shareholder Yield | 0.00% |
Stock Splits
The last split was a 1-for-10 reverse split on Jan 5, 2024.
| Last Split Date | Jan 5, 2024 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:10 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About SABS
What is SABS's market cap?
SAB Biotherapeutics has a market cap of $266.66M. Its enterprise value, which adds debt and subtracts cash, is $252.22M.
How many shares of SABS are outstanding?
SAB Biotherapeutics has 93.24M shares outstanding. The count is up 774.61% from a year earlier.
Does SABS pay a dividend?
No. SAB Biotherapeutics does not pay a dividend.
How much debt does SABS have?
SAB Biotherapeutics has $0 of total debt and $14.44M of cash and equivalents, a net cash position of $14.44M.
SABS pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors